What the changes say
- Transitioning from clinical development to commercialization for apitegromab in the United States and Europe.
- Heightened exposure to government drug pricing controls, most-favored-nation pricing, and tariffs under the Trump administration.
- Reliance on third-party manufacturers and fill-finish facilities for clinical and commercial supply.
What changed since the prior 10-K
New
- NewRisks Related to Product Development, Regulatory Approval and Commercialization
suitability of manufacturing sites prior to approval which could result in a delay in review timelines. GMP non-compliance at the third-party fill-finish facility could, in the most adverse scenario, even result in a negative CHMP opinion and refusal of the MAA by the European Commission
We have never commercialized a product and lack sales experience as we build our compliance, medical affairs, and commercial organizations for apitegromab.
- NewRisks Related to Product Development, Regulatory Approval and Commercialization
inability to obtain, applicable regulatory approvals would delay or prevent commercialization of apitegromab and could materially adversely impact our business and prospects
We may incur delays or fail in clinical development or in obtaining regulatory approvals for apitegromab, SRK-181, SRK-439, or future candidates.
- NewRisks Related to Product Development, Regulatory Approval and Commercialization
fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of apitegromab will be harmed
Failure to comply with ongoing international regulatory requirements and post-marketing obligations for apitegromab could result in penalties and reduced market potential.
- NewRisks Related to Product Development, Regulatory Approval and Commercialization
Any regulatory approvals that we receive for apitegromab may be subject to limitations on the approved uses for which the product may be marketed or contain requirements for potentially costly post-market testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of apitegromab
Approved uses of apitegromab may face marketing limitations, costly post-market Phase 4 trials, or severe regulatory sanctions like product recalls or fines.
- NewRisks Related to Our Business and Operations
increased costs and could negatively affect our ability to develop and commercialize our product candidates in a timely manner or within budget
We lack long-term supply agreements with many contract manufacturers for apitegromab, risking supply disruptions and delays if alternative suppliers must be onboarded.
- NewRisks Related to Our Business and Operations
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business
Executive orders and CMS initiatives like the GENEROUS Model push for most-favored-nation pricing and potential pharmaceutical tariffs, threatening revenues.
- NewRisks Related to Our Business and Operations
testing periods, with the GLOBE model proposed to begin on October 1, 2026 and the GUARD model proposed to begin on January 1, 2027
Upcoming pricing models like GLOBE and GUARD create strategic uncertainty, alongside strict anti-kickback and healthcare compliance laws governing our payor relationships.
- NewRisks Related to Our Business and Operations
significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for apitegromab
Uncertainty regarding third-party insurance coverage and reimbursement rates could limit demand and adequate payment for newly approved products like apitegromab.
- NewRisks Related to Our Intellectual Property
develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected
The patenting process is expensive, and we may fail to secure, defend, or control essential patent rights amidst unforeseen global events.
- NewRisks Related to Our Intellectual Property
Our product candidates may also require specific formulations to work effectively and efficiently, and these rights may be held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds
We may be required to use third-party companion diagnostic tests or proprietary formulations, risking high licensing costs or development halts if access is denied.
- NewRisks Related to Our Intellectual Property
could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates
Secret or prior-filed third-party patent applications could take priority over our owned or in-licensed patents, forcing us to obtain costly rights.
- NewRisks Related to Our Financial Condition and Capital Requirements
Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion
Our access to funding could be impaired by financial institution failures, liquidity constraints, or lack of timely government support for uninsured funds.
- NewRisks Related to Our Common Stock
We no longer qualify as a smaller reporting company as of January 1, 2026, which will increase our costs and demands on management
- NewRisks Related to Our Common Stock
investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock
Dropped
- DroppedRisks Related to Product Development, Regulatory Approval and Commercialization
commercialize apitegromab, SRK-181, SRK-439 or any future product candidates, and our business could be materially harmed
- DroppedRisks Related to Product Development, Regulatory Approval and Commercialization
The regulatory approval process for our product candidates in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, SRK-181, SRK-439 and future product candidates
Preclinical development is uncertain and programs like SRK-439 may experience delays.
- DroppedRisks Related to Product Development, Regulatory Approval and Commercialization
Furthermore, we intend to commercialize apitegromab globally, if approved. In order to do so, we must build, on a territory-by-territory basis, marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so
The regulatory approval process in the U.S., EU and other jurisdictions is lengthy and unpredictable.
- DroppedRisks Related to Product Development, Regulatory Approval and Commercialization
for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval
Government shutdowns or funding cuts at the FDA could delay BLA reviews.
- DroppedRisks Related to Product Development, Regulatory Approval and Commercialization
for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market
- DroppedRisks Related to Our Business and Operations
data sources are used to train artificial intelligence models, or the output of artificial intelligence systems reproduce or incorporate third party intellectual property rights, in each case without the right to do so
- DroppedRisks Related to Our Business and Operations
EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European Member States
- DroppedRisks Related to Our Business and Operations
potential commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies, capabilities and funding for our programs and underlying technology
- DroppedRisks Related to Our Intellectual Property
Because our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights
- DroppedRisks Related to Our Intellectual Property
challenge and subsequent invalidation or significant narrowing of claim scope in proceedings before the USPTO, or during litigation, under the revised criteria which could also make it more difficult to obtain patents
- DroppedRisks Related to Our Financial Condition and Capital Requirements
with which the Company has financial or business relationships, but could also include factors involving financial markets or the financial services industry generally
- DroppedRisks Related to Our Common Stock
We are a “smaller reporting company” as defined in the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation
Reworded
- 93% rewrittenRisks Related to Our Business and Operations
We may seek to enter into collaborations in the future with third parties, including for apitegromab, SRK-181, SRK-439 or potential product candidates. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected
Clarified that we may seek to enter collaborations specifically for apitegromab, SRK-181, SRK-439, and potential candidates, and added the consequence of failure.
- 93% rewrittenRisks Related to Our Intellectual Property
Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection
Added a direct warning that competitors could take advantage if we fail to secure broad patent protection.
- 82% rewrittenRisks Related to Our Business and Operations
Our reliance on third parties, such as manufacturers, third-party logistics providers, specialty distributors, specialty pharmacies, and patient service providers, may subject us to risks and may cause us to undertake substantial obligations, including financial obligations
Expanded third-party dependencies from just manufacturers to include logistics providers, specialty distributors, specialty pharmacies, and patient service providers.
Was: Our reliance on third parties, such as manufacturers, third-party logistics providers, specialty distributors, specialty pharmacies, and patient service providers, may subject us to risks relating to manufacturing scale-up and may cause us to undertake substantial obligations, including financial obligations
- 78% rewrittenRisks Related to Product Development, Regulatory Approval and Commercialization
Our clinical development strategy depends on the continued use and availability of certain third-party approved drug therapies
Updated clinical trials requiring approved SMN therapies to specifically name the OPAL trial for children under two alongside the ONYX extension study.
- 77% rewrittenRisks Related to Our Business and Operations
Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data
Retained substantially similar language regarding artificial intelligence risks and employee offerings.
- 74% rewrittenRisks Related to Our Business and Operations
Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations
Retained substantially similar language regarding healthcare legislative and regulatory reform measures.
- 68% rewrittenRisks Related to Our Business and Operations
Because we rely on a limited number of third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials, and, if approved, commercial materials, may become limited or interrupted or may not be of satisfactory quantity or quality
Added specific mention of fill-finish, raw materials, container closure systems, and potential quality issues during process scale-up with contract manufacturers.
- 65% rewrittenRisks Related to Product Development, Regulatory Approval and Commercialization
Competing therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of apitegromab, if approved, or any of our future product candidates, if successfully developed and approved
Retained substantially similar language regarding competition in the biopharmaceutical industry.
- 62% rewrittenRisks Related to Our Intellectual Property
Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO
- 54% rewrittenRisks Related to Our Business and Operations
Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business
- 54% rewrittenRisks Related to Product Development, Regulatory Approval and Commercialization
Receiving and maintaining regulatory approval of apitegromab in one jurisdiction does not mean that we will be successful in receiving or maintaining regulatory approval of apitegromab in other jurisdictions
Was: Receiving and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in receiving or maintaining regulatory approval of our product candidates in other jurisdictions
- 52% rewrittenRisks Related to Product Development, Regulatory Approval and Commercialization
The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or clinical trials of our product candidates in the same indications or other indications
- 52% rewrittenRisks Related to Our Financial Condition and Capital Requirements
The terms of our loan agreements place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business
Was: The terms of our loan and security agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business
- 51% rewrittenRisks Related to Our Financial Condition and Capital Requirements
Changes in tax law could adversely affect our business and financial condition
- 50% rewrittenRisks Related to Product Development, Regulatory Approval and Commercialization
We have received Rare Pediatric Disease designation for apitegromab for the treatment of SMA. However, a marketing application for apitegromab, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher
- 50% rewrittenRisks Related to Product Development, Regulatory Approval and Commercialization
Even if apitegromab receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
Was: Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
- 45% rewrittenRisks Related to Our Intellectual Property
As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain
- 42% rewrittenRisks Related to Our Business and Operations
Coverage and reimbursement may be limited or unavailable in certain market segments for apitegromab, if approved, which could make it difficult for us to sell apitegromab profitably
Was: Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably
- 42% rewrittenRisks Related to Product Development, Regulatory Approval and Commercialization
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market apitegromab in the EU, we may not be successful in commercializing apitegromab if and when it is approved
Was: If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market apitegromab, we may not be successful in commercializing apitegromab if and when it is approved
- 37% rewrittenRisks Related to Our Financial Condition and Capital Requirements
Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation
- 33% rewrittenRisks Related to Our Common Stock
We have issued a substantial number of warrants and equity awards from our equity plans which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders
- 25% rewrittenRisks Related to Our Common Stock
We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives
Was: We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
- 23% rewrittenRisks Related to Our Business and Operations
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
- 21% rewrittenRisks Related to Our Common Stock
The sale or issuance of our common stock to, or through, Jefferies may cause significant dilution and the sale of the shares of common stock acquired by Jefferies, or the perception that such sales may occur, could cause the price of our common stock to fall
All 69 risk factors
Headings as the filing states them, in filing order.
Other
- 01Summary of the Material Risks Associated with Our Business
Risks Related to Product Development, Regulatory Approval and Commercialization
- 02suitability of manufacturing sites prior to approval which could result in a delay in review timelines. GMP non-compliance at the third-party fill-finish facility could, in the most adverse scenario, even result in a negative CHMP opinion and refusal of the MAA by the European CommissionNew
- 03inability to obtain, applicable regulatory approvals would delay or prevent commercialization of apitegromab and could materially adversely impact our business and prospectsNew
- 04Our clinical development strategy depends on the continued use and availability of certain third-party approved drug therapies78% rewritten
- 05The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or clinical trials of our product candidates in the same indications or other indications52% rewritten
- 06If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
- 07Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates
- 08Our failure or any failure by these third parties to comply with these regulations would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws
- 09We have received Rare Pediatric Disease designation for apitegromab for the treatment of SMA. However, a marketing application for apitegromab, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher50% rewritten
- 10We may seek Fast Track designation, Breakthrough Therapy designation or PRIME designation for certain of our product candidates
- 11Receiving and maintaining regulatory approval of apitegromab in one jurisdiction does not mean that we will be successful in receiving or maintaining regulatory approval of apitegromab in other jurisdictions54% rewritten
- 12fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of apitegromab will be harmedNew
- 13Any regulatory approvals that we receive for apitegromab may be subject to limitations on the approved uses for which the product may be marketed or contain requirements for potentially costly post-market testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of apitegromabNew
- 14Even if apitegromab receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success50% rewritten
- 15If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market apitegromab in the EU, we may not be successful in commercializing apitegromab if and when it is approved42% rewritten
- 16Competing therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of apitegromab, if approved, or any of our future product candidates, if successfully developed and approved65% rewritten
Risks Related to Our Business and Operations
- 17Because we rely on a limited number of third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials, and, if approved, commercial materials, may become limited or interrupted or may not be of satisfactory quantity or quality68% rewritten
- 18increased costs and could negatively affect our ability to develop and commercialize our product candidates in a timely manner or within budgetNew
- 19Our reliance on third parties, such as manufacturers, third-party logistics providers, specialty distributors, specialty pharmacies, and patient service providers, may subject us to risks and may cause us to undertake substantial obligations, including financial obligations82% rewritten
- 20We will need to continue to grow our organization in certain areas, including our personnel, systems and relationships with third parties, in order to develop and potentially commercialize our product candidates, and we may experience difficulties in managing this growth
- 21Our internal computer systems, or those used by our contract research organizations, or other contractors or consultants, may fail or suffer security breaches, incidents or compromises
- 22Our employees, independent contractors, consultants, commercial partners, vendors and distributors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
- 23Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations74% rewritten
- 24Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our businessNew
- 25testing periods, with the GLOBE model proposed to begin on October 1, 2026 and the GUARD model proposed to begin on January 1, 2027New
- 26Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business54% rewritten
- 27Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data77% rewritten
- 28Additional laws and regulations governing international operations, including certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, could negatively impact or restrict our operations
- 29If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
- 30If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates23% rewritten
- 31Coverage and reimbursement may be limited or unavailable in certain market segments for apitegromab, if approved, which could make it difficult for us to sell apitegromab profitably42% rewritten
- 32significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for apitegromabNew
- 33We may seek to enter into collaborations in the future with third parties, including for apitegromab, SRK-181, SRK-439 or potential product candidates. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected93% rewritten
- 34Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the biotechnology or pharmaceutical industry, including within the business and financial communities, could be adversely affected
Risks Related to Our Intellectual Property
- 35Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection93% rewritten
- 36develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affectedNew
- 37We depend on intellectual property licensed from third parties. Failure to comply with our obligations under any of these licenses or termination of any of these licenses could result in the loss of significant rights, which would harm our business
- 38Our product candidates may also require specific formulations to work effectively and efficiently, and these rights may be held by others. We may develop products containing our compounds and pre-existing pharmaceutical compoundsNew
- 39As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain45% rewritten
- 40Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts
- 41Additionally, the Unitary Patent/Unified Patent Court system in Europe became fully operational in June 2023
- 42We may incur substantial costs as a result of litigation or other proceedings relating to our patents or the patents of our licensors, and we may be unable to protect our rights to our products and technology
- 43Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO62% rewritten
- 44could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidatesNew
- 45We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world
- 46Patent terms may result in inadequate protection for our product candidates, and we may be unable to obtain patent term extensions and data exclusivity for our product candidates, resulting in material harm to our business
- 47If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
- 48Third parties may assert that our employees or consultants have wrongfully used, disclosed, or misappropriated their confidential information or trade secrets
- 49If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
Risks Related to Our Financial Condition and Capital Requirements
- 50We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future
- 51We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of apitegromab, SRK-181, SRK-439 and any future product candidates
- 52Changes in tax law could adversely affect our business and financial condition51% rewritten
- 53Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation37% rewritten
- 54Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashionNew
- 55Our current investment policy focuses on preservation of capital. However, we could recognize losses on securities held in our investment portfolio, particularly if interest rates increase or economic and market conditions deteriorate
- 56The terms of our loan agreements place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business52% rewritten
Risks Related to Our Common Stock
- 57The price of our stock is volatile, and you could lose all or part of your investment
- 58We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
- 59The members of our board of directors, management, and their affiliates, own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
- 60We no longer qualify as a smaller reporting company as of January 1, 2026, which will increase our costs and demands on managementNew
- 61We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives25% rewritten
- 62investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stockNew
- 63We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively
- 64Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
- 65If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
- 66We may be subject to securities litigation, which is expensive and could divert management attention
- 67We have issued a substantial number of warrants and equity awards from our equity plans which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders33% rewritten
- 68Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
- 69The sale or issuance of our common stock to, or through, Jefferies may cause significant dilution and the sale of the shares of common stock acquired by Jefferies, or the perception that such sales may occur, could cause the price of our common stock to fall21% rewritten
Other Scholar Rock Holding 10-Ks
- FY2024 10-K risk factors67 risks
Company is a clinical-stage biopharmaceutical firm reliant on pipeline candidates apitegromab and SRK-181.
Filed Feb 27, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.